[Lani]

Unfortunately your title may be misleading. It was recommended for approval--it still needs to be approved by the European Commission. I doubt they will go against the recommendation, as it is likely in the longterm to save money (since time is money) although for several years it may cost more if biosimilar herceptin gets going anytime soon in EU.

In any case, this approval will in all likelihood be forthcoming in a couple of months.